Equities research analysts expect Tabula Rasa HealthCare Inc (NASDAQ:TRHC) to report earnings of $0.27 per share for the current fiscal quarter, according to Zacks. Six analysts have made estimates for Tabula Rasa HealthCare’s earnings, with estimates ranging from $0.21 to $0.33. Tabula Rasa HealthCare posted earnings per share of $0.08 during the same quarter last year, which would suggest a positive year-over-year growth rate of 237.5%. The business is expected to announce its next quarterly earnings results on Monday, November 5th.
According to Zacks, analysts expect that Tabula Rasa HealthCare will report full-year earnings of $0.82 per share for the current financial year, with EPS estimates ranging from $0.68 to $0.96. For the next year, analysts expect that the business will report earnings of $1.13 per share, with EPS estimates ranging from $0.90 to $1.50. Zacks’ EPS averages are a mean average based on a survey of sell-side research firms that that provide coverage for Tabula Rasa HealthCare.
Tabula Rasa HealthCare (NASDAQ:TRHC) last issued its quarterly earnings results on Tuesday, August 7th. The company reported $0.20 earnings per share for the quarter, beating analysts’ consensus estimates of $0.08 by $0.12. The business had revenue of $48.60 million during the quarter, compared to analyst estimates of $46.73 million. Tabula Rasa HealthCare had a negative net margin of 16.78% and a positive return on equity of 4.55%.
A number of analysts recently weighed in on TRHC shares. Robert W. Baird reissued a “buy” rating and issued a $70.00 price target on shares of Tabula Rasa HealthCare in a report on Wednesday, August 8th. Zacks Investment Research lowered shares of Tabula Rasa HealthCare from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. Stifel Nicolaus started coverage on shares of Tabula Rasa HealthCare in a report on Tuesday, September 11th. They set a “hold” rating and a $95.00 target price for the company. Oppenheimer lifted their target price on shares of Tabula Rasa HealthCare from $65.00 to $86.00 and gave the stock an “outperform” rating in a report on Thursday, August 23rd. Finally, Piper Jaffray Companies lifted their target price on shares of Tabula Rasa HealthCare to $71.00 and gave the stock an “overweight” rating in a report on Wednesday, August 8th. Three investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and a consensus price target of $68.08.
Shares of Tabula Rasa HealthCare stock traded down $4.79 during midday trading on Monday, reaching $78.18. The company had a trading volume of 480,000 shares, compared to its average volume of 346,744. The company has a debt-to-equity ratio of 0.11, a current ratio of 0.36 and a quick ratio of 0.33. The firm has a market cap of $1.76 billion, a P/E ratio of -1,976.50, a P/E/G ratio of 6.68 and a beta of 2.71. Tabula Rasa HealthCare has a 1-year low of $24.24 and a 1-year high of $91.16.
In other Tabula Rasa HealthCare news, CEO Calvin H. Knowlton sold 8,000 shares of Tabula Rasa HealthCare stock in a transaction on Friday, September 7th. The shares were sold at an average price of $85.98, for a total transaction of $687,840.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders have sold a total of 40,000 shares of company stock valued at $2,835,520 in the last ninety days. Company insiders own 14.00% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in shares of Tabula Rasa HealthCare by 29.7% during the second quarter. BlackRock Inc. now owns 2,119,507 shares of the company’s stock worth $135,288,000 after purchasing an additional 484,979 shares in the last quarter. Jennison Associates LLC boosted its position in shares of Tabula Rasa HealthCare by 29.5% during the second quarter. Jennison Associates LLC now owns 757,846 shares of the company’s stock worth $48,373,000 after purchasing an additional 172,693 shares in the last quarter. NN Investment Partners Holdings N.V. bought a new position in shares of Tabula Rasa HealthCare during the second quarter worth $29,439,000. Braun Stacey Associates Inc. boosted its position in shares of Tabula Rasa HealthCare by 199.0% during the second quarter. Braun Stacey Associates Inc. now owns 301,089 shares of the company’s stock worth $19,219,000 after purchasing an additional 200,394 shares in the last quarter. Finally, Bank of New York Mellon Corp boosted its position in shares of Tabula Rasa HealthCare by 34.2% during the second quarter. Bank of New York Mellon Corp now owns 214,062 shares of the company’s stock worth $13,664,000 after purchasing an additional 54,507 shares in the last quarter. 75.15% of the stock is currently owned by institutional investors.
About Tabula Rasa HealthCare
Tabula Rasa HealthCare, Inc operates as a healthcare technology company in the United States. It offers medication risk management, pharmacy cost management, and medicare risk adjustment services. The company offers its technology-enabled products and services to prescribers, pharmacists, and healthcare organizations for medication risk management and risk adjustment.
Featured Story: Understanding Compound Annual Growth Rate (CAGR)
Get a free copy of the Zacks research report on Tabula Rasa HealthCare (TRHC)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Tabula Rasa HealthCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tabula Rasa HealthCare and related companies with MarketBeat.com's FREE daily email newsletter.